Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05504252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin

Study acronym: METIMMOX-2
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 30, 2025 to Jan 31, 2028 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 30, 2027 to Mar 1, 2028 · Site details revised at 3 of 3 sitesv4 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 30, 2027 to Mar 1, 2028
    • Site details revised at 3 of 3 sites
  2. Primary completion date: Sep 1, 2025 to Sep 30, 2025 Completion date: Dec 31, 2027 to Dec 30, 2027v3 Show 1 more changeShow less
    • Completion date: Dec 31, 2027 to Dec 30, 2027
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 1, 2022 to Oct 5, 2022 · Site details revised at 3 of 3 sites · Study description expanded, about 2 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Sep 1, 2022 to Oct 5, 2022
    • Site details revised at 3 of 3 sites
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient (pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that can be transformed into an immunogenic condition by short-course oxaliplatin-based therapy, and may achieve durable disease control or even tumor eradication by the addition of immune checkpoint blockade therapy to the standard-of-care oxaliplatin-based treatment.
Trial Details
NCT Number NCT05504252
Lead Sponsor University Hospital, Akershus
Collaborators: Oslo University Hospital, St. Olavs Hospital
Conditions Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov